Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0VJ5N
|
|||
| Former ID |
DCL000223
|
|||
| Drug Name |
SB-705498
|
|||
| Synonyms |
SB-705498; 501951-42-4; SB705498; SB 705498; UNII-T74V9O0Y2W; (R)-1-(2-bromophenyl)-3-(1-(5-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)urea; T74V9O0Y2W; 1-(2-bromophenyl)-3-[(3R)-1-[5-(trifluoromethyl)pyridin-2-yl]pyrrolidin-3-yl]urea; N-(2-Bromophenyl)-N'-[(3R)-1-[5-(trifluoromethyl)-2-pyridinyl]-3-pyrrolidinyl]urea; 1-(2-Bromophenyl)-3-[(3R)-1-[5-(trifluoromethyl)-2-pyridyl]pyrrolidin-3-yl]urea; JYILLRHXRVTRSH-GFCCVEGCSA-N; MLS006011113; SCHEMBL1350298; GTPL4311; CHEMBL207433; BMCL163287 Compound 15; BDBM20504
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Rhinitis [ICD-11: FA20; ICD-10: J31.0] | Phase 2 | [1] | |
| Migraine [ICD-11: 8A80; ICD-10: G43, G43.9; ICD-9: 346] | Discontinued in Phase 1 | [2], [3] | ||
| Company |
GlaxoSmithKline
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H16BrF3N4O
|
|||
| Canonical SMILES |
C1CN(CC1NC(=O)NC2=CC=CC=C2Br)C3=NC=C(C=C3)C(F)(F)F
|
|||
| InChI |
1S/C17H16BrF3N4O/c18-13-3-1-2-4-14(13)24-16(26)23-12-7-8-25(10-12)15-6-5-11(9-22-15)17(19,20)21/h1-6,9,12H,7-8,10H2,(H2,23,24,26)/t12-/m1/s1
|
|||
| InChIKey |
JYILLRHXRVTRSH-GFCCVEGCSA-N
|
|||
| CAS Number |
CAS 501951-42-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14880783, 15329850, 24191010, 24714966, 45982146, 49688578, 80688310, 103489680, 134338885, 135302994, 136340373, 137663487, 141108962, 152159579, 152258263, 160647099, 162011660, 162205200, 174007206, 174529520, 178101128, 186007046, 189024877, 198989585, 208265534, 223705156, 224286843, 227570003, 242588168, 246888321, 249735426, 251963246, 252151430, 252811273
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Transient receptor potential cation channel V1 (TRPV1) | Target Info | Blocker | [4], [5] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Inflammatory mediator regulation of TRP channels | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Trk receptor signaling mediated by the MAPK pathway | |||
| Trk receptor signaling mediated by PI3K and PLC-gamma | ||||
| Reactome | TRP channels | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01424514) SB705498 Proof of Concept Chamber Challenge in Subjects With Non Allergic Rhinitis. U.S. National Institutes of Health. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4311). | |||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022354) | |||
| REF 4 | Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009 Aug 1;78(3):211-6. | |||
| REF 5 | The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov. 2007 May;6(5):357-72. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.